MedTrace Logo

SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors

NCT07728942 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-08-10

No results posted yet for this study

Summary

This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.

Conditions

  • Metastatic Solid Tumors

Interventions

DRUG

SLR-108

SLR-108 is an antibody-radionuclide conjugate.

DRUG

SLX-1411

SLX-1411 is a non-radiolabeled antibody.

Sponsors & Collaborators

  • Solve Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-04
Primary Completion
2028-01-31
Completion
2028-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07728942 on ClinicalTrials.gov